Literature DB >> 23763404

Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004-2010.

Reena Mahajan1, Stephen J Liu, R Monina Klevens, Scott D Holmberg.   

Abstract

OBJECTIVES: Centers for Disease Control and Prevention has recommended a 1-time HCV test for persons born from 1945 through 1965 to supplement current risk-based screening. We examined indications for testing by birth cohort (before 1945, 1945-1965, and after 1965) among persons with past or current HCV.
METHODS: Cases had positive HCV laboratory markers reported by 4 surveillance sites (Colorado, Connecticut, Minnesota, and New York) to health departments from 2004 to 2010. Health department staff abstracted demographics and indications for testing from cases' medical records and compiled this information into a surveillance database.
RESULTS: Of 110, 223 cases of past or current HCV infection reported during 2004-2010, 74, 578 (68%) were among persons born during 1945-1965. Testing indications were abstracted for 45, 034 (41%) cases; of these, 29 ,544 (66%) identified at least 1 Centers for Disease Control and Prevention-recommended risk factor as a testing indication. Overall, 74% of reported cases were born from 1945 to 1965 or had an injection drug use history.
CONCLUSIONS: These data support augmenting the current HCV risk-based screening recommendations by screening adults born from 1945 to 1965.

Entities:  

Mesh:

Year:  2013        PMID: 23763404      PMCID: PMC4007868          DOI: 10.2105/AJPH.2013.301211

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  32 in total

1.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.

Authors:  Gordon Guyatt; Andrew D Oxman; Elie A Akl; Regina Kunz; Gunn Vist; Jan Brozek; Susan Norris; Yngve Falck-Ytter; Paul Glasziou; Hans DeBeer; Roman Jaeschke; David Rind; Joerg Meerpohl; Philipp Dahm; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2010-12-31       Impact factor: 6.437

2.  GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology.

Authors:  Gordon H Guyatt; Andrew D Oxman; Holger J Schünemann; Peter Tugwell; Andre Knottnerus
Journal:  J Clin Epidemiol       Date:  2010-12-24       Impact factor: 6.437

3.  Evaluation of acute hepatitis C infection surveillance --- United States, 2008.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-11-05       Impact factor: 17.586

4.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias).

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn Vist; Regina Kunz; Jan Brozek; Pablo Alonso-Coello; Victor Montori; Elie A Akl; Ben Djulbegovic; Yngve Falck-Ytter; Susan L Norris; John W Williams; David Atkins; Joerg Meerpohl; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-01-19       Impact factor: 6.437

5.  GRADE guidelines 6. Rating the quality of evidence--imprecision.

Authors:  Gordon H Guyatt; Andrew D Oxman; Regina Kunz; Jan Brozek; Pablo Alonso-Coello; David Rind; P J Devereaux; Victor M Montori; Bo Freyschuss; Gunn Vist; Roman Jaeschke; John W Williams; Mohammad Hassan Murad; David Sinclair; Yngve Falck-Ytter; Joerg Meerpohl; Craig Whittington; Kristian Thorlund; Jeff Andrews; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-08-11       Impact factor: 6.437

6.  GRADE guidelines: 5. Rating the quality of evidence--publication bias.

Authors:  Gordon H Guyatt; Andrew D Oxman; Victor Montori; Gunn Vist; Regina Kunz; Jan Brozek; Pablo Alonso-Coello; Ben Djulbegovic; David Atkins; Yngve Falck-Ytter; John W Williams; Joerg Meerpohl; Susan L Norris; Elie A Akl; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-07-30       Impact factor: 6.437

7.  GRADE guidelines: 9. Rating up the quality of evidence.

Authors:  Gordon H Guyatt; Andrew D Oxman; Shahnaz Sultan; Paul Glasziou; Elie A Akl; Pablo Alonso-Coello; David Atkins; Regina Kunz; Jan Brozek; Victor Montori; Roman Jaeschke; David Rind; Philipp Dahm; Joerg Meerpohl; Gunn Vist; Elise Berliner; Susan Norris; Yngve Falck-Ytter; M Hassan Murad; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-07-30       Impact factor: 6.437

8.  GRADE guidelines: 8. Rating the quality of evidence--indirectness.

Authors:  Gordon H Guyatt; Andrew D Oxman; Regina Kunz; James Woodcock; Jan Brozek; Mark Helfand; Pablo Alonso-Coello; Yngve Falck-Ytter; Roman Jaeschke; Gunn Vist; Elie A Akl; Piet N Post; Susan Norris; Joerg Meerpohl; Vijay K Shukla; Mona Nasser; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-07-30       Impact factor: 6.437

9.  HCV screening practices and prevalence in an MCO, 2000-2007.

Authors:  Douglas W Roblin; Bryce D Smith; Cindy M Weinbaum; Miriam E Sabin
Journal:  Am J Manag Care       Date:  2011       Impact factor: 2.229

10.  GRADE guidelines: 7. Rating the quality of evidence--inconsistency.

Authors:  Gordon H Guyatt; Andrew D Oxman; Regina Kunz; James Woodcock; Jan Brozek; Mark Helfand; Pablo Alonso-Coello; Paul Glasziou; Roman Jaeschke; Elie A Akl; Susan Norris; Gunn Vist; Philipp Dahm; Vijay K Shukla; Julian Higgins; Yngve Falck-Ytter; Holger J Schünemann
Journal:  J Clin Epidemiol       Date:  2011-07-31       Impact factor: 6.437

View more
  11 in total

Review 1.  Hepatitis C Antibody Positive, RNA Negative.

Authors:  Keith C Summa; Haripriya Maddur
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-08-02

2.  Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

Authors:  Eleanor E Friedman; Hazel D Dean; Wayne A Duffus
Journal:  Public Health Rep       Date:  2018-06-06       Impact factor: 2.792

Review 3.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

4.  A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.

Authors:  John T Nguyen; Josiah D Rich; Bradley W Brockmann; Fred Vohr; Anne Spaulding; Brian T Montague
Journal:  J Urban Health       Date:  2015-08       Impact factor: 3.671

5.  Increasing Birth Cohort Screening for Chronic Hepatitis C in a Primary Care Clinic with Panel Management.

Authors:  Christopher Jai Balkissoon; Michelle DeCoux Hampton
Journal:  J Community Health       Date:  2019-12

6.  Hepatitis C Infection Among Hispanics in California.

Authors:  Catherine A Cummins; Erlyana Erlyana; Dennis G Fisher; Grace L Reynolds
Journal:  J Addict Dis       Date:  2015

7.  An Electronic Health Record-based Intervention to Promote Hepatitis C Virus Testing Among Adults Born Between 1945 and 1965: A Cluster-randomized Trial.

Authors:  Alex D Federman; Natalie Kil; Joseph Kannry; Evie Andreopolous; Wilma Toribio; Joanne Lyons; Mark Singer; Anthony Yartel; Bryce D Smith; David B Rein; Katherine Krauskopf
Journal:  Med Care       Date:  2017-06       Impact factor: 2.983

8.  Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States.

Authors:  Joshua A Barocas; Abriana Tasillo; Golnaz Eftekhari Yazdi; Jianing Wang; Claudia Vellozzi; Susan Hariri; Cheryl Isenhour; Liisa Randall; John W Ward; Jonathan Mermin; Joshua A Salomon; Benjamin P Linas
Journal:  Clin Infect Dis       Date:  2018-08-01       Impact factor: 20.999

Review 9.  State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.

Authors:  Cecilia Trucchi; Andrea Orsi; Cristiano Alicino; Laura Sticchi; Giancarlo Icardi; Filippo Ansaldi
Journal:  J Immunol Res       Date:  2016-10-24       Impact factor: 4.818

10.  Locations and reasons for initial testing for hepatitis C infection--chronic hepatitis cohort study, United States, 2006-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-08-16       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.